In the evolving field of molecular biology, the study of antisense oligonucleotides has reached a significant milestone with the development of SRP-5051. As someone deeply interested in the progression of peptide-conjugated technologies, I have followed the trajectory of this compound, also known as vesleteplirsen, wi 6 Sept 2022—SRP-5051, also known as vesleteplirsen, is an investigational peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) that binds Read more th great curiosity. This article explores the mechanics, intent, and recent history of this investigational agent.
Understanding the Mechanism: SRP-5051 and PPMO Chemistry
At its core, SRP-5051 is a next-generation antisense oligonucleotide, specifically a peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO). The primary innovation behind this molecule is the integration of a cell-penetrating peptide (CPP) with the traditional PMO structure.
The SRP-5051, a peptide conjugated PMO, was engineered to solve a long-standing challenge in oligonucleotide delivery: intracellular uptake. By attaching a specific peptide, the molecule is designed to increase the ability of the exon-skipping agent to enter the cell nucleus, where it can interact with pre-mRNA. This approach effectively makes SRP-5051 an exon-51 skipping therapy that is significantly more potent than its predecessors.
The Goal of Enhan Pharmacology and toxicology of eteplirsen and SRP-5051 ced Exon Skipping
The fundamental objective of this technology is clear: SRP-5051 aims to better prompt exon-skipping and dystrophin production. In preclinical and early-phase models, the results were striking. When we look at the data, SRP-5051 increases exon skipping and dystrophin production in a manner that outperforms older weekly-dosed therapies.
For instance, clinical reports indicated that SRP-5051 dosed monthly at 30 mg/kg delivered mean exon skipping of 10.79% and mean dystrophin expression of 6.55%. These figures are particularly impressive given the shift from weekly dosing to a monthly administration schedule, which is made possible by the efficiency of the peptide conjugation.
Contextualizing the History and Research
As an investigational agent, the journey of this compound has been closely monitored by the scientific community. The Two-Part Study for Dose Determination of Vesle A cell-penetrating peptide enhances delivery and efficacy teplirsen (SRP-5051), also registered under identifiers such as NCT04004065, sought to define the safety and efficacy profile of the drug.
Throughout the MOMENTUM study, researchers focused on 14 Nov 2024—Sarepta discontinuedSRP-5051development due to safety concerns, despite promising Phase 2 results in dystrophin expression and exon skipping.Read more how SRP-5051 was designed to bind to exon 51 of the dystrophin pre-mRNA. By doing so, it forces the cellular machinery to skip this specific exon during mRNA processing. Because SRP-5051 is a new generation antisense oligonucleotide, it garnered significant attention regarding its potential to treat Duchenne Muscular Dystrophy (DMD).
Navigating Challenges: Safety and Regulatory Status
It is important to note that the path for any DMD drug candidate SRP-5051 is rarely linear. FDA Places Hold on Phase 2 DMD Trial for SRP-5051 During the clinical trials, there were instances where the FDA placed a clinical hold on SRP-5051 due to observations of hypomagnesemia in participants. While the hold was eventually lifted after further analysis, it highlighted the balance between therapeutic efficacy and safety in peptide-based medicine.
Recently, the landscape changed significantly when the developers, Sarepta Therapeutics, made the decision to discontinue the development of the program. Despite the promising molecular data, the decision reflects the rigorous standards applied to all investigational ag SRP-5051, an antisense oligonucleotide of the PPMO type, ents. As someone who reviews these developments, it serves as a reminder that the transition from a laboratory-proven peptide to a finalized, safe therapeutic is a complex process.
Summary of Findings
To summarize the technical aspects:
* Entity: SRP-5051 (Vesleteplirsen).
* Classification: Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO).
* Functional Goal: To skip exon 5 Compared to Exondys 51,SRP-5051 contains a peptide designed to increase the ability of the exon-skipping agentto get into cells, and is dosed once every Read more 1 of the dystrophin gene.
* Clinical Observation: Monthly dosing showed higher efficacy compared to previous iterations of exon-skipping technology.
While the story of SRP-5051 as a potential therapy has reached a conclusion, the underlying science—specifically the use of cell-penetrating peptides to improve the delivery of antisense oligonucleotides—remains a vibrant area of explor Phase 2 Multiple-Ascending-Dose Study of SRP-5051 ation. The data generated by the SRP-5051 PPMO is investigational work will undoubtedly inform future research in this field for years to come.